Frank Yan

Dr. Yan is the Operating Partner at 3E Bioventures Capital and currently the General Manager of N.B. Quadriga, a joint venture biotechnology company developing first-in-class therapeutics for brain tumors. He has 17 years of pharmaceutical research and development and operation experience in both U.S. and China, having held positions with increasing responsibilities in Novartis, Roche, and GlaxoSmithKline. Dr. Yan has broad experience in various disease areas including oncology, neurosciences, and infectious diseases, and has close to 50 publications and patents. He received his B.Sc. in Physics from Fudan University and Ph.D. in Chemical Biology from New York University.